CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Aptevo (APVO) up almost 60% on clinical trial news

By Joyanta Acharjee

15:06, 23 November 2021

Red blood cells at risk in leukemia
A patient with acute myeloid leukaemia showed complete remission after treatment with APVO436 – Photo: Shutterstock

Aptevo stock was up on Tuesday as the Seattle-based biotech company said a patient with acute myeloid leukaemia (AML) undergoing clinical trials showed complete remission after one cycle of therapy.

At 10am EST (UTC-5) the stock was up 59% at $10.30.

AML is a cancer of the blood and bone marrow.

Trials of APVO436

Aptevo is currently testing its APVO436 drug in a Phase 1/1b open-label clinical trial in patients with AML and high-grade myelodysplastic syndrome.

The goal of the study is to determine if APVO436 treatments can improve the quality of remission in high-risk AML patients by reducing the residual chemotherapy-resistant measurable residual disease (MRD) burden.


43,837.10 Price
-0.300% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00


0.64 Price
+2.000% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168


2,026.99 Price
+0.360% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 22:00 (UTC)
Spread 0.50


15,793.50 Price
-0.490% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 22:00 (UTC)
Spread 1.8

MRD is where a small number of leukaemic cells remain in the bloodstream after chemotherapy.

Aptevo's APVO436 drug at a glance– Photo: Aptevo

Potential for ‘complete remissions’

Aptevo said it believes that APVO436 has the potential to help AML patients achieve complete remissions without MRD and thereby reduce their risk of leukaemic relapses.

It also believes the use of APVO436 for targeting MRD in AML may be associated with a very low risk of cytokine release syndrome (CRS) as well as an increased likelihood of responses, as both are inversely correlated with the leukaemic burden of the patients.

If successful, deepening the remission to an MRD-negative remission using this strategy could translate into an improved overall survival in AML, Aptevo said.

Read more: Astrazeneca jumps after successful anti-cancer drug trials

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading